Jason brings over 20 years of research experience in cancer biology, inflammation, drug discovery and new target ID/validation to UNITY. He has led numerous therapeutic projects from concept through preclinical development and IND filing. Prior to UNITY, Jason was the director of therapeutic antibody discovery and translational medicine at Achaogen, where he was responsible for establishing and advancing a pipeline of novel biological therapeutics. Previously, Jason was an immuno-oncology target identification consultant for Five Prime Therapeutics and prior to that, served as director of biology for Igenica Biotherapeutics. At the Novartis Institutes for Biomedical Research, Jason was a Senior Research Investigator focused on the discovery and development of oncology biotherapeutics. Jason received his Ph.D. in cellular & molecular pharmacology with a focus in tumor biology from the University of Arizona and completed his postdoctoral work in apoptosis & inflammation research under John Reed at the Sanford Burnham Prebys Medical Discovery Institute.